Lifetime Obesity Exposure Underestimated in Cancer Care, Study Reveals

A recent groundbreaking study published in the European Society for Medical Oncology (ESMO) Real World Data and Digital Oncology has revealed that the extent of lifetime obesity exposure in cancer patients is significantly underestimated when clinicians rely solely on a single body mass index (BMI) measurement at the time of cancer treatment initiation. This underestimation carries substantial implications for cancer prognostication and the delivery of personalized care. The study, led by Professor Simon Lord from the Department of Oncology at the University of Oxford and funded by the World Cancer Research Fund, analyzed real-world obesity rates in a large cohort of over 79,000 patients across 13 different cancer types in England between 2013 and 2023. The findings demonstrated a notable disparity: more than half of the individuals receiving systemic anticancer treatment had a history of obesity, whereas only approximately one in four were classified as obese at the point their treatment commenced. This stark difference underscores that many patients with a history of obesity may not be identified as such by current clinical assessment methods, which typically focus on a patient's weight status at the time of diagnosis or treatment initiation. Obesity is a well-established and growing risk factor for numerous cancers, including breast, colorectal, liver, endometrial, esophageal, kidney, pancreatic, ovarian, thyroid, multiple myeloma, and meningioma. The mechanisms linking excess body fat to cancer risk are complex and involve factors such as chronic inflammation, altered hormone levels (like estrogen and insulin-like growth factor-1), and changes in cell and blood vessel growth. Previous research has also highlighted that a longer duration of overweight and obesity during adulthood significantly increases the incidence of various obesity-related cancers. Studies suggest that high BMI at cancer diagnosis is associated with increased risks of developing a second primary cancer and can worsen several aspects of cancer survivorship, including quality of life, recurrence, progression, and prognosis. The implications of underestimating lifetime obesity exposure are profound. For instance, the study points out that for pancreatic cancer, obesity at the start of treatment was only 13.7%, but the lifetime obesity prevalence was a much higher 55.8%. This gap means that crucial historical health data that could influence treatment decisions, chemotherapy dosing, and patient outcomes might be overlooked. This comprehensive view of a patient's weight history is vital for informing healthcare provision and tailoring treatment approaches effectively. Experts also suggest that the overall contribution of obesity to cancer risk may be substantially underestimated due to limitations in epidemiological studies, such as prediagnostic weight loss and reliance on single-point BMI measurements rather than cumulative or lifetime exposure. The 'PLUS framework' identifies these biases, advocating for the inclusion of lifetime weight exposure and central obesity measures for a more accurate risk assessment. The relevance of this research extends globally, particularly to countries like India, where the prevalence of overweight and obesity is on a significant rise across all age groups and communities. National health surveys in India show a steady increase in obesity rates in both urban and rural populations, with a noticeable surge among adolescents and young adults. This trend is linked to shifting dietary habits, increased reliance on processed foods, and reduced physical activity. Studies specific to the Indian population have already established a strong association between obesity and an increased risk of breast cancer, as well as poorer survival outcomes among Indian women with breast cancer. The rising number of obesity-related cancer cases is being observed in both younger and older adults in many countries, including India. Therefore, the findings of this EMJ-featured study are particularly pertinent for India, emphasizing the need for a holistic approach to patient assessment and public health interventions aimed at weight management from an early age. To address this critical gap, the research highlights the opportunity to consider patients' history of obesity alongside their current health when making clinical decisions. Future research should explore how lifetime BMI versus BMI at treatment initiation correlates with cancer outcomes to resolve unanswered questions. Integrating obesity control more fully into cancer prevention and public health frameworks is essential for making a significant impact on cancer outcomes worldwide. While the link between obesity and cancer development is well established, its precise impact on cancer outcomes and treatment response is still being fully elucidated, necessitating comprehensive and longitudinal tracking of patients' weight histories.

Frequently Asked Questions

Read Full Story on Quick Digest